Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Using the Intra-patient Escalation Dosing Regimen in Patients With Advanced Uveal Melanoma

NCT02570308 is registered in ClinicalTrials.gov with Immunocore Ltd as lead sponsor.

NCT NCT02570308
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02570308 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Using the Intra-patient Escalation Dosing Regimen in Patients With Advanced Uveal Melanoma
Lead sponsor
Immunocore Ltd
Phase
Phase 1/2
Overall status
Completed
Start date
February 29, 2016
Completion date
October 17, 2022
Enrollment
146 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

uveal melanoma